The market for medical testing and imaging is continuing to expand, but new healthcare regulations mean that a number of testing sites will require change of ownership
Houston, Texas (PRWEB) January 31, 2008
Bederra Corporation (BDRR.pk) President and CEO Graham Williams has published comments on the ongoing plans for the company.
"Our research shows a steady increase in demand for imaging services, as the diagnostic capability of these machines help the consumer,” Williams said. “Continued technological advances in the field indicate that the larger companies and research establishments recognize the future need.
“The market for medical testing and imaging is continuing to expand, but new healthcare regulations mean that a number of testing sites will require change of ownership," he said. "A tremendous opportunity has opened up for our company and our shareholders. We have completed one acquisition and are finalizing our next acquisition. We plan to make several more acquisitions in the future." Mr. Williams was referring to the company's recent activity with Diagnos, Inc. and Lumar Diagnostics Imaging, the first two of several acquisition targets.
"The company has been carefully examining this segment of the industry for some time,” Williams said. “PET/CT imaging is a wonderful technology that can help catch early stage health problems from cancer to Alzheimer's, dementia and heart disease. As we locate and acquire these companies, we will be able to see consistent revenue enhancement and increased shareholder value. We are to be a positive impact on people's health.”
Bederra Corporation is a publicly traded company trading under the ticker symbol BDRR.pk. It operates through Diagnos, a wholly owned subsidiary, located at 2000 N. Loop W., Suite 100, Houston, Texas, 77018. Diagnosis, Inc. was formed to provide medical diagnostic imaging services utilizing state of the art Positron Emission Tomography / Computed Tomography (PET/CT) technology. This is new technology with only 18 machines in the Houston area serving a population of over 5 million. The technology is proven and accepted by Medicare and all private insurance carriers. The current medical disciplines that use this technology are oncology, neurology, cardiology, and urology.
Safe Harbor Statement
Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.
281 540 0500
# # #